South Korea's Samsung Biologics Secures 88% Stake in PolyPeptide Group Amid Takeover Bid

MT Newswires · 3d ago
01:38 AM EDT, 10/13/2026 (MT Newswires) -- South Korea-listed Samsung Biologics secured an 87.92% stake in PolyPeptide Group (PPGN.SW) under its takeover offer for the Swiss contract manufacturer, according to a Tuesday release. The main offer period for the tender offer expired on Monday. If the offer is declared successful, an additional acceptance period will run from Oct. 19 through Oct. 30. The transaction remains subject to regulatory clearances and the removal of transfer restrictions and voting restrictions from PolyPeptide's association articles, among other conditions. PolyPeptide shareholders will vote on these matters at an extraordinary general meeting on Oct. 26.